![Joseph Pearlberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Joseph Pearlberg
Director/Board Member at
NUVALENT, INC.
Net worth: 568 067 $ as of 31/05/2026
Profile
Joseph Pearlberg is currently an Independent Director at Nuvalent, Inc. since 2021, a Director at Neomorph, Inc., an Associate at The Broad Institute, Inc., and a Vice President at Deerfield Management Co. LP (Private Equity) since 2017.
Former roles include Medical Director at Sanofi and Vice President-Clinical Development at Infinity Pharmaceuticals, Inc. from 2016 to 2017.
Education includes a doctorate from Harvard University conferred in 1994, an undergraduate degree from the University of Pennsylvania conferred in 1985, and a doctorate from The University of California, San Francisco conferred in 1999.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/06/2025 | 5,146 ( 0.01% ) | 568 067 $ | 31/05/2026 |
Joseph Pearlberg active positions
| Companies | Position | Start |
|---|---|---|
| NUVALENT, INC. | Director/Board Member | 01/01/2021 |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Corporate Officer/Principal | - |
Neomorph, Inc.
 Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Manufactures health drugs | Director/Board Member | - |
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Private Equity Investor | 01/07/2017 |
Former positions of Joseph Pearlberg
| Companies | Position | End |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/07/2017 |
| SANOFI | Chief Tech/Sci/R&D Officer | - |
Training of Joseph Pearlberg
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
97
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Health Technology |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Finance |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Manufactures health drugs | Health Technology |
- Stock Market
- Insiders
- Joseph Pearlberg
